How will nanotechnology lead to better control of asthma?

Bumhee Yang, Hayoung Choi, Sang-Heon Kim, Ho Joo Yoon, Hyun Lee

Abstract

Asthma is a common inflammatory disease of the lungs characterized by reversible airway obstruction, bronchial hyper-responsiveness, and chronic airway inflammation (1). The most widely used therapies for asthma include inhaled corticosteroids and bronchodilators (short- or long-acting β2-adrenergic agonists or muscarinic antagonists). Although most patients with asthma respond well to inhaled corticosteroids, asthma control is poor in some patients who require maximal dosages (2).